New Diabetes Med, Brenzavvy, Available through Mark Cuban’s Online Pharmacy

Brenzavvy (bexagliflozin), an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor, is now available through the Mark Cuban Cost Plus Drug Company (Cost Plus Drugs). A 30-day supply is available from Cost Plus Drugs for $47.85 plus shipping and handling.

Developed by TheracosBio, Brenzavvy was approved in January 2023 and is indicated to improve glycemic control in adults with type 2 diabetes. SGLT2 inhibitors are a class of prescription medicines that lower blood sugar by causing the kidneys to remove sugar from the body through urine.

“Our main goal is to make as many products as possible available to those who need them at an affordable price. I’m a diabetic myself, so products like Brenzavvy are a top priority,” Alex Oshmyansky, co-founder and chief executive officer of Cost Plus Drugs, said in a press release.

The FDA approval is based on results from a clinical program that evaluated the safety and efficacy in 23 clinical trials enrolling more than 5,000 adults with type 2 diabetes mellitus. In one phase 2 trial of 288 patients, Brenzavvy was found to be well-tolerated and provided a durable, clinically meaningful improvement in glycemic control over 96 weeks.

Phase 3 studies showed that Brenzavvy significantly reduced hemoglobin A1c and fasting blood sugar after 24 weeks, either as a monotherapy and in combination with metformin. In one phase 3 trial that enrolled 426 patients, Brenzavvy was found noninferior to glimepiride, an oral antidiabetic, in lowering hemoglobin A1c and was associated with significantly fewer hypoglycemic events than glimepiride. In another phase 3 trial of 312 patients, bexagliflozin lowered hemoglobin A1c levels by 0.37% compared with placebo.

Although it is not approved for weight or blood pressure reduction, modest decreases in both weight and blood pressure have been observed in the clinical program.